Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Warning Letter: Exoskeleton Firm Dodged Communication With FDA Over Postmarket Study, Failed To Assemble Surveillance Plan

This article was originally published in The Gray Sheet

Executive Summary

An FDA warning letter sent to Argo Medical Technologies, now named ReWalk Robotics, outlines the company's failure to conduct mandatory postmarket surveillance activities on its ReWalk bionic walking assistance system. The missive to Argo also lays out a timeline of events that describes how the agency chased after the company.

You may also be interested in...



Market Intel: Exoskeletons Stretch Into Stroke And Mobility Rehab Markets To Ramp Up Growth

When it comes to helping patients recover from spinal cord injuries and stroke, the use of exoskeletons – a robotic suit that supports a person's weight and helps them move their limbs – is gaining traction by physical therapists in rehabilitation centers and clinical settings. Several exoskeleton companies such as ReWalk, Ekso Bionics and Parker Hannifin are already marketing their own versions of these smart, robotic-assisted body suits in various countries worldwide. Despite facing significant barriers, such as high device cost and lack of reimbursement, recent advances in robotics, microelectronics, battery technologies and product designs are the driving forces behind the continuous innovation in this field. Companies hope the dramatic life-changing impact exoskeletons have today in helping the paralyzed will also have implications for other mobility-challenged individuals, including those living with Parkinson's disease, multiple sclerosis, cerebral palsy and the elderly.

FDA Warning Letters For Olympus, Fujifilm, Pentax: Duodenoscope-Makers Fail To Meet Agency's Post-Market Surveillance Study Order

US FDA sent the letters to Olympus Corp., Fujifilm Medical Systems USA Inc. and Pentax Medical after the firms failed to meet obligations to conduct Sec. 522 post-market studies on their duodenoscopes, the use of which caused a number of antibiotic-resistant superbug infections in 2013 and 2014.

FDA '522' Guidance: 15-Month Deadline To Comply With Postmarket Order

The agency has issued a final guidance on Sec. 522 postmarket study orders about five years after a draft version. In the interim, Congress stipulated a 15-month deadline for companies to start the FDA-mandated studies, a requirement emphasized in the new document.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT034570

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel